DOBUTAMINE
Generic: DOBUTAMINE
HospiraManufacturer
INTRAVENOUSRoute
DOBUTAMINE HYDROCHLORIDEActive Substance
1993-11-29Original Approval
DOBUTAMINE is FDA application ANDA074086, sponsored by HOSPIRA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class I2014-01-10
DOBUTamine Injection, USP, 250 mg per 20 mL, 20 mL Single-dose Fliptop Vial, Rx only, Manufactured for Hospira Inc., LakPresence of Particulate Matter: Discolored solution due to a chip in the glass at the neck of the vi
Class II2025-05-28
DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, FDiscoloration; discolored solution from cracked vials
Top Reported Reactions
1
DRUG INEFFECTIVE
919 reports
2
OFF LABEL USE
663 reports
3
CARDIOGENIC SHOCK
502 reports
4
DEATH
500 reports
5
MULTIPLE ORGAN DYSFUNCTION SYNDROME
465 reports
6
CONDITION AGGRAVATED
451 reports
7
SEPSIS
448 reports
8
GENERAL PHYSICAL HEALTH DETERIORATION
383 reports
9
NAUSEA
378 reports
10
STRESS
373 reports